The Wyandotte woman had worked at Blue Cross for 32 years and was denied a religious accommodation to the insurer's vaccine ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Moderna (MRNA – Research Report) today and set a price ...

RESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes ...

Health professionals recommend vaccines before traveling to celebrate the holidays with family. If you missed the early fall ...

The Cambridge-based company’s latest COVID shot was approved three weeks earlier than last year, according to a statement ...

RBC Capital lowered the firm’s price target on Moderna (MRNA) to $62 from $75 and keeps a Sector Perform rating on the shares following a COVID vaccine sale beat that was primarily driven by an ...

Moderna posted a surprising third-quarter profit, driven by cost-cutting and higher-than-expected Covid vaccine sales.

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...

Moderna Inc.'s stock was higher but off its early highs Thursday, after the company's third-quarter earnings showed an unexpected profit as well as revenue that beat estimates by a wide margin. The ...